Table 1. Studies (more than 50 cases) on radiotherapy for nmCRPC.

Author, year	Total no.	No. of N0/N1	RT dose (Gy)	Median follow-up (m)	Outcomes
White et al. (16), 2015	51	51/0	50	54	3y FFLF: 85%; 5y FFLF: 81%; 5y CSS: 65%; 5y OS: 35%
Akimoto et al. (17), 2003	53	53/0	69	35	3y CSS: 94%; 3y CFFS: 78%; 5y CSS: 87%; 5y CFFS: 56%
Sasaki et al. (18), 2009	140	84/28	66	20.7	5y OS: 48.1%; 5y CPFS: 36.7%
Ogawa et al. (19), 2008	84	58/10	66	26.9	3y OS: 67%; 3y LCR: 93%; 3y PFS: 61%
Nakamura et al. (20), 2004	61	45/15	60	17	5y OS: 51.6%; 5y PFS: 43.5%

m, month; y, year; FFLF, free from local failure; CSS, cancer-specific survival; OS, overall survival; CFFS, clinical failure-free survival; RT, radiotherapy; LCR, locoregional control rate; CPFS, clinical progression-free survival; PFS, progression-free survival.